Drug intelligence / Profile preview

NH140068

Development stage: Unknown
Lead developer: Jiangsu Nhwa Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

NH140068 is a novel small molecule antipsychotic developed by Jiangsu Enhua Pharmaceutical for the treatment of schizophrenia. It is designed as a multi-target ligand with a pharmacological profile characterized by partial agonism at dopamine D2 and serotonin 5-HT1A receptors, combined with antagonism at serotonin 5-HT2A receptors. This balanced activity aims to provide efficacy against both positive and negative symptoms of schizophrenia while minimizing common side effects such as extrapyramidal symptoms (EPS) and metabolic disturbances. The drug is currently undergoing clinical evaluation in China, where it has progressed into Phase 2 trials.

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on NH140068.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NH140068.

Explore the full profile